This site is intended for Healthcare professionals only.

Lupin receives FDA approval for generic Lodosyn tablets

Lupin receives FDA approval for generic Lodosyn tablets

Mumbai: Pharma Major Lupin announced that it has received final approval for its Carbidopa Tablets, 25 mg from the United States Food and Drug Administration (FDA) to market a generic version of Aton Pharma, Inc.’s Lodosyn® Tablets, 25 mg.

Lupin’s Carbidopa Tablets, 25 mg is the AB rated generic equivalent of Aton Pharma, Inc.’s Lodosyn® Tablets, 25 mg. It is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

Carbidopa Tablets, 25 mg had annual sales of approximately USD 21.9 million in the US (IMS MAT June 2017).

READ  Lupin launches generic psoriasis drug in US


Source: Press Release
0 comment(s) on Lupin receives FDA approval for generic Lodosyn tablets

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted